Clinical trial
Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept…
NCT00223301 · University of Texas Southwestern Medical Center, Other · Completed
Key facts
| NCT number | NCT00223301 |
|---|---|
| Title | Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis |
| Official title | A One-Year Prospective, Randomized, Placebo-Controlled, Double-Blind, Phase II/III Safety Trial of Combination Therapy With IFN Beta-1a (Avonex) and Mycophenolate Mofetil (Cellcept) in Early Multiple Sclerosis |
| Lead sponsor | University of Texas Southwestern Medical Center, Other |
| Collaborators | Roche Pharma AG Industry Biogen |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | Mycophenolate Mofetil (cellcept) |
| Enrollment | 24 |
| Start date | Jul 1, 2004 |
| Primary completion | Mar 1, 2007 |
| Completion | Mar 1, 2007 |
| First posted | Sep 22, 2005 |
| Last update posted | Apr 22, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: